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Abstract

To test the hypothesis that suppression of ornithine decarboxylase (ODC) activity blocks the promotion of target
cells in the outer root sheath of the hair follicle initiated by Raf/MEK/ERK activation, we crossed mice
overexpressing an activated MEK mutant in the skin (K14-MEK mice) with two transgenic lines overexpressing
antizyme (AZ), which binds to ODC and targets it for degradation. K14-MEK mice develop spontaneous skin
tumors without initiation or promotion. These mice on the ICR background were crossed with K5-AZ and K6-AZ
mice on both the carcinogenesis-resistant C57BL/6 background and the sensitive DBA/2 background. Expression
of AZ driven by either the K5 or K6 promoter along with K14-MEK dramatically delayed tumor incidence and
reduced tumor multiplicity on both backgrounds compared with littermates expressing the MEK transgene
alone. The effect was most remarkable in the MEK/K6-AZ mice from the ICR/D2 F1 cross, where double
transgenic mice averaged less than one tumor per mouse for more than 8 weeks, while K14-MEK mice averaged
over 13 tumors per mouse at this age. Putrescine was decreased in MEK/AZ tumors, while spermidine and
spermine levels were unaffected, suggesting that the primary role played by AZ in this system is to inhibit
putrescine accumulation. MEK/AZ tumors did not show evidence of apoptosis, but there was a 15–20% decrease
in S-phase cells and a 40–60% decrease in mitotic cells in MEK/AZ tumors. These results indicate that the
principal effect of AZ may be to slow cell growth primarily by increasing G2 /M transit time.

Introduction
The use of transgenic animals provides a unique system for the study of the events and gene interactions
involved in the development of tumors. This is particularly true of models of skin tumor development, where the
genetic and biochemical alterations that occur in response to the two-stage initiation/promotion protocol have
been studied extensively in recent years (reviewed in ( 1 )). In addition, strong promoters are available that can
target transgene expression specifically to cells of interest ( 2 ). The experiments reported here make use of
several transgenic mouse models to gain a greater understanding of the role played by ornithine decarboxylase
(ODC) in skin tumorigenesis.
ODC catalyzes the conversion of ornithine to putrescine, the first step in the biosynthesis of intracellular
polyamines. High levels of ODC can transform NIH/3T3 cells ( 3 , 4 ), and induction of ODC activity and changes in
polyamine levels have been demonstrated in a variety of experimental systems designed to study neoplastic
growth. Increased ODC activity has been associated with in vitro transformation by such oncogenes as H- ras and
v- src ( 5 – 7 ). We have shown that ODC is controlled both transcriptionally and translationally by the Ras
effector pathways Raf/MEK/ERK and PI 3-kinase ( 8 ), and ODC is also a transcriptional target of both c- myc and
the WT1 tumor suppressor ( 9 , 10 ). In vivo , transgenic mice have been used to establish that overexpression of
ODC in the outer root sheath (ORS) of the hair follicle using both the Keratin 5 (K5) and Keratin 6 (K6) promoters
is a sufficient stimulus for skin tumor promotion ( 11 – 13 ), and this increased ODC activity can cooperate with
the Raf/MEK/ERK pathway to promote invasiveness of keratinocytes from K6/ODC mice ( 14 ). Elevated ODC
activity was detected in the spontaneous skin tumors that develop on mice expressing an activated MEK protein
from the K14 promoter (K14-MEK mice ( 15 )). Our results using K14-MEK mice treated with the ODC inactivator
α-difluoromethylornithine (DFMO) provide strong evidence that induction of ODC activity is critical to MEKinduced skin tumorigenesis and link the induction of ODC during skin tumor promotion with alterations in Ras
signal transduction pathways ( 15 ).
To examine the role of ODC in the molecular mechanism of tumor development in response to Ras effector
pathway activation, tumor formation on both carcinogenesis-sensitive and resistant backgrounds was analyzed
in K14-MEK mice crossed with transgenic lines designed to block ODC activity. These lines use keratin promoters
to overexpress either a dominant negative form of ODC (ODCdn), which we have shown decreases ODC activity
when expressed in the skin ( 16 ), or antizyme (AZ) ( 17 ), an important endogenous regulator of ODC and

polyamine homeostasis. The wild type form of ODC has an extremely short half life (20–30 min), and its
degradation is mediated by AZ, which binds to the monomeric form of ODC, preventing formation of the
enzymatically active homodimer, and then targets ODC for degradation ( 18 ). In addition to its effects on ODC,
AZ also controls polyamine content by inhibiting polyamine transport into cells ( 19 ). We have shown previously
using AZ transgenic mice that AZ suppresses tumor growth in the classic DMBA/TPA skin tumorigenesis model
( 17 ) and a UV carcinogenesis model that utilized mice heterozygous for the patched tumor suppressor gene
( 20 ).
AZ expression is driven by either the K5 or K6 promoter in these experiments ( 17 ), and ODCdn is driven by the
K6 promoter ( 16 ). The constitutive K5 and K14 promoters are active in the same cell populations ( 21 ) and the
K6 promoter, while expressed at very low levels in untreated skin, is upregulated by hyperproliferative stimuli
( 22 ), which is provided in this model by the activated MEK protein. Therefore, MEK is expressed in the same
cell populations as the ODC inhibitor proteins in the double transgenic lines. The use of these transgenic lines
targets inhibition of ODC activity to a specific subpopulation of epidermal keratinocytes, rather than the more
general effect seen with an inhibitor such as DFMO, thus providing valuable model systems to evaluate the role
of ODC and polyamines in skin tumorigenesis.
The results show that overexpression of AZ driven by either the K5 or K6 promoter at the time of the initiating
stimulus reduces total tumor numbers and dramatically delays tumor formation in K14-MEK mice. Tumors that
form exhibit slower growth rates, characterized by a decrease in S-phase cells and a much larger reduction of
mitosis, suggesting a prolonged G 2 transit time. No measurable increase in apoptosis was observed in MEK/AZ
tumors, indicating that in this model AZ is acting to slow tumor proliferation without affecting the rate of
programmed cell death.

Materials and methods
Transgenic mice

K14-MEK (line 6) mice ( 15 ) were maintained on the ICR background by breeding hemizygous K14-MEK males
with ICR females (Charles River Laboratories, Wilmington, MA). K5-AZ mice and K6-AZ (line 52) mice ( 17 ) were
maintained on both the C57BL/6 and DBA/2 backgrounds for at least 5 generations by breeding hemizygous
males with nontransgenic females (Jackson Laboratories, Bar Harbor, ME). K6-ODCdn mice ( 16 ) were
maintained on the DBA/2 background by breeding hemizygous males with nontransgenic females for at least 5
generations. For tumorigenesis experiments, K14-MEK males were bred with K5-AZ, K6-AZ or K6-ODCdn
females. The progeny were genotyped by PCR analysis of tail DNA as described ( 15 – 17 ) and examined for
tumor formation.

Tumor induction experiments

F1 crosses of ICR/B6 and ICR/D2 mice were used for all experiments. Mice expressing either the K14-MEK
transgene alone or in combination with K6-ODCdn, K5-AZ or K6-AZ were analyzed for spontaneous tumor
formation. Tumors were counted weekly or biweekly after the first tumors became visible on the K14-MEK mice
(usually 3–5 weeks of age). Both male and female mice were used in all experiments, and all experiments were
performed using littermates. Mice were killed at the times noted in the text.

Biochemical analyses

Tumor samples were harvested and homogenized as described previously ( 17 ), and ODC was assayed at 37°C
by measuring the release of 14 CO 2 from L-[1- 14 C] ornithine ( 23 ). For polyamine analysis in the skin, mice were
killed at 7 weeks while in the resting phase of the hair cycle. Animals were shaved, and dermis and epidermis
were isolated as described previously ( 17 ). Animals were killed for analysis of polyamines in tumors at 8 weeks

for K14-MEK mice and 13 weeks for MEK/AZ mice. All samples were acid extracted using 10% TCA and analyzed
for polyamines using reverse phase HPLC analysis ( 24 ).

AZ immunohistochemistry

Tumors were removed immediately after sacrifice, fixed overnight in 10% neutral buffered formalin, embedded
in paraffin, and 5 μm sections were obtained. Antiserum to AZ was produced in rabbits immunized with a
purified recombinant polyhistidine-tagged AZ fusion protein and then purified using an AZ-affinity column as
described previously ( 17 ). Following deparaffinization and rehydration in graded alcohols, tumor sections were
heated in Vector Antigen Unmasking Solution (Vector Laboratories, Burlingame, CA.) in a microwave oven (88–
95°C, 3 × 5 min) before nonspecific binding sites were blocked with goat serum. Sections were incubated
overnight at 37°C in a humidified chamber with rabbit anti-AZ antibody at 0.6 ng/μl dilution followed by
incubation with biotinylated goat anti-rabbit antibody (1:500 dilution; Vector Laboratories). Slides were then
incubated with streptavidin horseradish peroxidase (1:1000 dilution; Dako, Carpinteria, CA). Expression of AZ
was localized by a final incubation with 3,3′-diaminobenzidine tetrahydrochloride (DAB, Vector Laboratories).
Sections were counterstained with hematoxylin and pictures taken on a Nikon TMS microscope.

Cell proliferation analysis

Cell proliferation was analyzed using PCNA immunohistochemistry, BrdU labeling and phospho-histone H3
(ser10) immunohistochemistry in MEK and MEK/AZ tumors. Mouse monoclonal anti-PCNA antibody (1:500
dilution; Santa Cruz Biotechnology, Santa Cruz, CA) was used along with biotinylated goat anti-mouse antibody
(1:500 dilution; Dako). Slides were then incubated with streptavidin horseradish peroxidase (1:1000 dilution;
Dako) and PCNA was localized with 3-amino-9-ethylcarbazole chromogen (Vector Laboratories) and hematoxylin
counterstain. When BrdU was used, mice were injected i.p. with 100 mg/kg body weight and killed 2 h later.
Paraffin-embedded sections were subjected to zinc-buffered formalin postfixation and antigen retrieval as
described previously ( 25 ), incubated overnight at 4°C with 1 U/ml peroxidase-conjugated mouse monoclonal
anti-BrdU Fab fragments (Roche, Indianapolis, IN) and BrdU staining was visualized with DAB and hematoxylin
counterstain. For phospho-histone H3 (ser10), sections were deparaffinized and subject to antigen retrieval as
described above for AZ staining and then incubated with rabbit anti-phospho-histone H3 (ser10) (1:200, Upstate,
Lake Placid, NY). Staining was visualized with the Vectastain Elite ABC kit (Vector Laboratories) with DAB
chromogen and hematoxylin counterstain. Labeling index (%) for both BrdU and phospho-histone H3 was
calculated by dividing labeled nuclei by the total number of cells counted per tumor section. Between 4 and 6
tumor sections from multiple mice were counted and averaged for each determination, and results are
expressed as the mean ± SD.

Apoptosis analysis

The TUNEL assay was used to analyze the number of apoptotic cells in paraffin-embedded tumor sections
isolated from MEK and MEK/AZ mice. The 3′-OH end labeling of apoptotic cell DNA was performed using an
ApopTag Plus in situ peroxidase detection kit (Chemicon, Purchase, NY).

Differentiation analysis

Tumor differentiation was evaluated in MEK and MEK/AZ tumors at approximately 8 weeks for K14-MEK mice
and 13–14 weeks for MEK/AZ mice. Paraffin sections were incubated in an anti-keratin 1 antibody (1:500;
BAbCo, Richmond, CA) and visualized with a Vectastain Elite ABC kit and DAB (Vector Laboratories).

Statistical analysis

Tumor counts taken over a time course were compared using two-way ANOVA. Tumor incidence data were
compared using a log-rank test of the curves. Counts of BrdU-labelled or phospho-histone H3-labelled nuclei
were compared using the Student's t -test. Polyamine levels were also compared using the Student's t -test.

Results
Tumor formation in K14-MEK mice and double transgenic mice

Our results using systemic DFMO treatment suggest that ODC induction is necessary for tumor promotion and
maintenance after initiation by MEK activation ( 15 ). To extend these experiments, we have crossed K14-MEK
mice with transgenic lines that utilize the K6 promoter to overexpress a dominant-negative ODC (K6-ODCdn
mice) or the K5 and K6 promoters to express AZ (K5-AZ mice and K6-AZ mice). ODCdn and AZ mice were
backcrossed for at least five generations onto the tumor promotion-resistant C57BL/6 strain and the more
sensitive DBA/2 strain ( 26 , 27 ). The K14-MEK mice were maintained on the ICR strain, and all experiments
described use F1 crosses to generate double transgenic mice and littermate controls expressing MEK alone. In
both K6-ODCdn mice and K6-AZ mice, expression of the transgene is induced in the ORS and in the interfollicular
epidermis in response to hyperplasia. Since K14-MEK mice exhibit spontaneous hyperplasia, the K6 promoter
would be expected to be up-regulated in MEK-expressing cells of the double-transgenic mice ( 22 ). The K5 and
K14 proteins are coexpressed in the same cell lineages ( 28 ); therefore K5-AZ mice have constitutive
overexpression of the transgene in the same cells that overexpress MEK.
Skin tumors arise spontaneously in K14-MEK mice on the ICR background at multiple sites on the body, without
the need for chemical initiation or promotion ( 15 ). Introduction of the DBA/2 strain through F1 crosses
increased K14-MEK tumorigenicity in the ICR/D2 progeny compared with our previous studies using the ICR
strain ( 15 ). Expression of AZ from either the K5 or K6 promoter in ICR/D2 crosses reduced both tumor incidence
and tumor multiplicity very effectively in the double transgenic mice compared with K14-MEK mice ( Figure 1A,
B ). There was a significant lag in tumor onset in mice expressing AZ on this background, and several double
transgenic mice remained tumor-free throughout the experiment ( Figure 1A ). Tumor multiplicity was reduced
at 8 weeks from an average of 13.5 tumors per mouse in the K14-MEK mice to 0.9 tumors per mouse in MEK/K6AZ double transgenic mice and 5.1 tumors per mouse in MEK/K5-AZ mice. It was usually necessary to sacrifice
K14-MEK mice at eight weeks due to large tumor burden. At 12 weeks of age MEK/K6-AZ double transgenic mice
still averaged only 4.3 tumors per mouse, while MEK/K5-AZ mice averaged about 11.6 tumors per mouse
( Figure 1B ). No tumors were observed on non-transgenic littermates or littermates expressing only the AZ
transgene.

Fig. 1. Effect of AZ expression on spontaneous tumor formation in K14-MEK mice on the ICR/D2 and ICR/B6
backgrounds. On the ICR/D2 background, tumor incidence ( A ) and number of tumors per mouse ( B ) were
assessed for K14-MEK mice (filled circle, N = 20) and double transgenic MEK/K5-AZ (filled square, N = 8) and

MEK/K6-AZ mice (filled diamond, N = 13). P < 0.001 when tumor incidence of MEK/K6-AZ mice is compared with
K14-MEK mice; P < 0.0001 when tumor multiplicity of MEK/K6-AZ mice or MEK/K5-AZ mice is compared with
K14-MEK mice. P < 0.0001 when tumor multiplicity of K5-AZ mice is compared with K6-AZ mice. On the ICR/B6
background, tumor incidence ( C ) and number of tumors per mouse ( D ) were assessed for K14-MEK mice (filled
circle, N = 30) and double transgenic MEK/K5-AZ (filled square, N = 12) and MEK/K6-AZ mice (filled diamond, N =
13). P < 0.05 when tumor incidence of MEK/K5-AZ mice is compared with K14-MEK mice; P < 0.0001 when tumor
multiplicity of MEK/K6-AZ mice or MEK/K5-AZ mice is compared with K14-MEK mice. On this background
differences between the two AZ lines were not statistically significant. For both ICR/D2 and ICR/B6, tumor
multiplicity values are expressed as the mean ± SEM for each time point.
The reduced tumor burden in the double transgenic mice was the result not only of fewer total tumors, but also
because tumors in double transgenic mice were much smaller than those in their littermates (data not shown).
Expression of MEK on the ICR/D2 background resulted in a high rate of tumor expansion, often leading to the
merging of several small tumors into one large mass. K14-MEK mice also frequently had many papilloma-like
lesions associated with the vibrissa follicles of the muzzle, making it difficult to count tumor numbers accurately.
This pattern of tumor development is similar to that seen previously in K5 ras mice ( 29 ). MEK/K5-AZ mice
exhibited much smaller tumors than MEK mice, while expression of AZ from the K6 promoter blocked tumor
formation almost completely ( Figure 1A, B and data not shown). Many tumors in MEK/K6-AZ mice were too
small to be seen through the coat of the animal, even though double transgenic mice were killed 4 weeks after
their MEK littermates.
Crosses were also performed using AZ-overexpressing mice on the C57BL/6 background ( Figure 1C, D ). As
expected, K14-MEK mice from the ICR/B6 cross were more resistant to tumor formation compared with both
ICR/D2 mice ( Figure 1A, B ) and the parental ICR strain ( 15 ). In fact, 20% of ICR/B6 MEK mice remained tumorfree for 15 weeks, with an average of 8.2 tumors per mouse visible by this age ( Figure 1C, D ). As with the DBA/2
crosses, expression of AZ from either the K5 or K6 promoter delayed tumor formation and dramatically reduced
tumor multiplicity, with MEK/K5-AZ mice averaging 2.3 tumors per mouse and MEK/K6-AZ mice averaging 3.9
tumors per mouse at 15 weeks ( Figure 1D ).
Expression of K6-ODCdn in the skin of K14-MEK ICR/D2 mice delayed tumor onset by approximately 3 weeks in
double transgenic mice compared with K14-MEK mice, with 100% of K14-MEK mice ( N = 20) developing tumors
by 5 weeks and 100% of MEK/K6-ODCdn mice developing tumors by 8 weeks ( N = 16). When tumors were
counted at sacrifice (8 weeks), expression of ODCdn did not result in a statistically significant difference in tumor
number, and ODC activity was not decreased in MEK/K6-ODCdn tumors (data not shown). These results are
similar to our previous results using DMBA/TPA treatment of K6-ODCdn mice, where expression of the ODCdn
protein did not lead to a significant reduction in ODC activity or polyamine content ( 16 ). Therefore, in contrast
to our in vitro experiments, where the ODC dominant negative mutant effectively reduced ODC activity and
reverted oncogenic transformation by H-Ras and RhoA ( 7 ), this is not the case in an in vivo model.

Analysis of tumors for transgene expression and proliferation

We have shown previously that expression of the MEK transgene results in about a 3-fold increase in MEK
protein in transgenic skin, resulting in a high level of phospho-ERK in tumor sections from K14-MEK mice ( 15 ).
The expression pattern of AZ was analyzed in tumors by immunohistochemistry in K14-MEK mice and MEK/AZ
mice on both ICR/D2 and ICR/B6 backgrounds ( Figure 2 ). AZ was undetectable in K14-MEK tumors ( Figure 2A,
C ) and was not consistently detected in MEK/K5-AZ tumors, although a faint expression was observed
throughout the basal layer of most samples ( Figure 2E, G ). Consistent AZ expression was observed from the
inducible K6 promoter ( Figure 2I, K ). Strong (though irregular) expression of AZ in MEK/K6-AZ tumors appeared
in the suprabasal layer, with lighter staining in the proliferating basal cell layer. This is consistent with the

pattern of induction of the K6 promoter by hyperplasia in the tumors ( 22 ), and has been seen in other models
utilizing the K6 promoter for transgene expression ( 11 , 30 ). Immunohistochemistry using antibodies directed
to the endogenous keratin 6 protein confirmed expression of the K6 promoter in the suprabasal layer of
MEK/K6-AZ tumors (data not shown).

Fig. 2. AZ expression and cell proliferation in K14-MEK and MEK/AZ tumors. Immunohistochemistry for AZ
( A , C , E , G , I , and K ) and PCNA ( B , D , F , H , J, and L ) was performed as described in the Materials and
Methods on serial sections of tumors from K14-MEK mice and MEK/AZ double transgenic mice on both the
ICR/B6 and ICR/D2 backgrounds. Little or no AZ expression is apparent in both K14-MEK tumors (A, C) and
MEK/K5-AZ tumors (E, G), while strong AZ staining is detected in the suprabasal cells of MEK/K6-AZ tumors (I, K).
Numerous PCNA-positive nuclei are present in the basal layer of all tumors. Note that AZ staining (I, K) and PCNA
staining (J, L) are visible in different cell layers in MEK/K6-AZ tumors.
Visual inspection of tumors from MEK and MEK/AZ mice demonstrated a dramatic decrease in tumor volume in
double transgenic mice, as discussed above. Serial sections of tumor samples used for AZ immunohistochemistry
were analyzed for PCNA-positive nuclei as a measure of tumor proliferation in MEK and MEK/AZ mice. Results
are shown for both ICR/D2 mice and ICR/B6 mice ( Figure 2 ). PCNA is an endogenous cell proliferation marker
and can be used to identify cell cycle populations. Dark-staining nuclei represent S-phase cells, light-staining
nuclei represent G 1 -S and G 2 cells, cells with cytoplasmic staining usually represent mitotic cells and nonstaining nuclei represent quiescent cells ( 31 ). The results show that, although tumors from K14-MEK mice are
visually much larger than tumors from MEK/AZ mice, all tumors are proliferating in the basal cell layer at the
time points examined ( Figure 2B, D, F, H, J, L ). Tumors were generally isolated at sacrifice: 16–18 weeks for all
mice on the ICR/B6 background, 8–9 weeks for K14-MEK on the ICR/D2 background and 13–14 weeks for
MEK/AZ on the ICR/D2 background.
To quantitate proliferation differences in MEK and MEK/AZ tumors, tumor-bearing mice were injected with BrdU
and killed 2 h later, when the labelling index was calculated by counting the number of S-phase cells and dividing
it by the number of total cells. Results are shown for ICR/B6 crosses ( Figure 3 ), and results in ICR/D2 mice were
similar (data not shown). There was about a 15–20% decrease in labeling index in both MEK/AZ lines when
compared with the K14-MEK tumors ( Figure 3 ). Because this decrease alone most likely cannot explain the
dramatic difference observed in tumor size with the expression of the AZ transgene, we also examined the
phosphorylation of histone H3 in tumors as a measure of mitosis ( 32 ). There was a much more substantial
decrease in mitotic cells (40–60%) in double transgenic tumors compared with tumors expressing the MEK
transgene alone ( Figure 3 ), suggesting that expression of AZ decreases tumor growth rate by increasing the
G 2 transit time between S-phase and mitosis.

Fig. 3. K14-MEK tumor growth is inhibited by AZ. Tumor proliferation was analyzed by BrdU incorporation and
phospho-histone H3 immunohistochemistry as described in the Materials and Methods on tumor sections from
K14-MEK mice and MEK/AZ double transgenic mice. Statistical analysis revealed a significant decrease in the
percentage of both S-phase cells (* P < 0.05) and mitotic cells (** P < 0.005; *** P < 0.0001) in MEK/AZ tumors.

Analysis of tumors and skin for ODC activity and polyamine levels

ODC activity and protein levels are known to be constitutively upregulated in DMBA/TPA-induced tumors
( 33 , 34 ) and in tumors induced by MEK expression from the K14 promoter ( 15 ). ODC activity was analyzed in
tumor extracts from K14-MEK mice and double transgenic MEK/K5-AZ mice and MEK/K6-AZ mice in F1 ICR/B6
crosses. Although results were variable because of the heterogeneous nature of the tumor tissue and the
directed expression of the transgenes, ODC activity was reduced by about 50% in tumors from MEK/K5-AZ mice
and 60% in MEK/K6-AZ tumors compared with K14-MEK single transgenic mice ( Figure 4 ). This result is
consistent with previous results showing that AZ expression reduced ODC activity in chemically induced tumors
( 17 ). ICR/D2 tumors were not analyzed for ODC activity because the very small size of tumors from the double
transgenic mice did not allow accurate ODC activity determinations.

Fig. 4. ODC activity in tumors derived from K14-MEK and MEK/AZ mice on the ICR/B6 background. Mice were
killed and tumors were processed for ODC activity as described in the Materials and Methods. Results are shown
for tumors from K14-MEK mice ( N = 6), MEK/K5-AZ mice ( N = 5) and MEK/K6-AZ mice ( N = 4). All ODC assays
were performed in duplicate. Values are shown as means ± SEM and differences were not statistically
significant.
Polyamines were also analyzed in skin and tumors from ICR/B6 mice ( Table 1 ). Polyamine levels are shown for
both epidermis and dermis of the following genotypes: wild-type, K14-MEK, K5-AZ, K6-AZ, MEK/K5-AZ and
MEK/K6-AZ ( Table 1 ). There is no measurable putrescine in any of the skin samples. This is consistent with the
very low levels of ODC in the skin. There was a trend toward increased spermidine and spermine in the dermis of
K14-MEK mice, and levels of spermidine and spermine were closer to those of WT mice in dermis of the double
transgenics, particularly MEK/K5-AZ mice ( Table 1 ). However, these differences were not statistically
significant. This is not unexpected since both the AZ and MEK transgenes are expressed in limited cell
populations, while the polyamines measured reflect levels in the entire epidermis or dermis. This makes it very
difficult to detect even large changes in a small number of cells. This is especially true of the K6-AZ, which is
induced by hyperproliferation but expressed in a very limited number of cells within the hair follicle ORS under
unstimulated conditions.
Table 1.
Polyamine levels in skin and tumors from ICR/B6 mice
Genotype
Putrescine
Epidermis
WT
BD
K14-MEK
BD
K5-AZ
BD
MEK/K5-AZ BD
K6-AZ
BD
MEK/K6-AZ BD
Dermis
WT
BD
K14-MEK
BD
K5-AZ
BD
MEK/K5-AZ BD
K6-AZ
BD
MEK/K6-AZ BD
Tumor
K14-MEK
335 ± 45
MEK/K5-AZ 274 ± 32
MEK/K6-AZ 59 ± 11 a
a
P < 0.01 versus K14-MEK.
BD, below the limit of detection.

Spermidine (nmol/g wet weight ± SEM) Spermine
221 ± 22
262 ± 66
230 ± 12
283 ± 45
278 ± 80
254 ± 64

196 ± 13
221 ± 49
216 ± 17
193 ± 15
263 ± 80
228 ± 61

169 ± 20
295 ± 86
181 ± 33
204 ± 39
202 ± 21
246 ± 52

129 ± 10
219 ± 68
134 ± 26
136 ± 12
151 ± 24
168 ± 39

1046 ± 128
949 ± 72
903 ± 41

99 ± 21
93 ± 9
118 ± 22

For skin measurements, mice were killed at 7 weeks and dermis was separated from the epidermis as described
in the Materials and Methods. When tumors were analyzed, mice were killed after 8 weeks for K14-MEK mice

and after 13 weeks for MEK/K5-AZ mice and MEK/K6-AZ mice. Skin and tumors were harvested and processed
for polyamine analysis as described in the Materials and Methods. N = 3–6 mice for each measurement.
K14-MEK tumors, which have high levels of ODC, contain large amounts of putrescine and spermidine, but have
less spermine than skin ( Table 1 ). Consistent with the induced expression of AZ from the K6 promoter,
putrescine levels were reduced significantly in MEK/K6-AZ tumors but not in tumors from MEK/K5-AZ mice
( Table 1 ). Again, since polyamines are measured in whole tumor extracts, these numbers do not necessarily
reflect localized polyamine changes brought about by the expression of AZ from the K5 promoter, which would
be more restricted in tumors than K6-AZ expression. Spermidine and spermine levels were not changed
significantly in either double transgenic line. The putrescine reduction seen in MEK/K6-AZ tumors is similar to
results previously reported using DFMO to inhibit ODC in several mouse models of skin tumor formation
( 12 , 13 , 15 ).

Measurement of apoptosis in tumor samples

Tumor sections from both MEK and MEK/AZ mice were analyzed by TUNEL analysis to determine the extent of
apoptosis ( Figure 5 ). Results are shown for ICR/B6 mice and were similar for ICR/D2 mice. The rapidly growing
K14-MEK tumors showed very little evidence of apoptosis ( Figure 5A ). No increase in apoptosis was observed in
MEK/AZ tumors, despite their very small size, compared with mice expressing the MEK transgene alone ( Figure
5B, C ). Many of the TUNEL-positive cells in the MEK/AZ tumors appeared at the edge of the sections, suggesting
the possibility of randomly occurring DNA fragmentation due to necrosis or the normal process of
differentiation-dependent molecular breakdown ( 35 ). Immunohistochemical analysis of cleaved caspase 3 and
western blot analysis of PARP cleavage from MEK and MEK/AZ tumors showed no difference among the groups
examined (data not shown), also suggesting that MEK/AZ tumors do not undergo apoptosis at an increased rate
compared with MEK tumors.

Fig. 5. Apoptosis and differentiation in tumors from K14-MEK, MEK/K5-AZ and MEK/K6-AZ mice on the ICR/B6
background. Apoptotic cells in K14-MEK tumors ( A ), MEK/K5-AZ tumors ( B ) and MEK/K6-AZ tumors ( C ) were
visualized by TUNEL assay as described in the Materials and Methods. Results are representative of multiple
tumors taken from at least three separate mice in each group. Very little apoptosis was detected in K14-MEK
tumors, and increases in apoptosis were not seen with expression of the AZ transgene in combination with MEK.
Keratin 1 expression was analyzed in tumors from the same groups ( D , E , F ) as a measure of differentiation.

Analysis of tumor differentiation

Previous results have shown that spontaneous tumors from K14-MEK mice on the ICR background were welldifferentiated papillomas, as measured by keratin 1 protein expression. Similar results were seen here for K14MEK mice on both the ICR/D2 (data not shown) and ICR/B6 backgrounds when analyzed at 8 weeks ( Figure 5D ).
Mice expressing the MEK transgene alone typically must be killed at this age due to large tumor burdens,
especially on the ICR/D2 background. Expression of AZ from either the K5 or K6 promoter did not affect the
expression pattern of keratin 1 when analyzed on either background ( Figure 5E, F ). Western blot analysis
confirmed that keratin 1 levels were not different in MEK and MEK/AZ tumors (data not shown). For these
measurements double transgenic mice were typically killed at 13–15 weeks.

Discussion
Our previous studies have shown that ODC is highly induced in tumors from K14-MEK mice, and ODC activity and
high putrescine are necessary for MEK-induced skin carcinogenesis ( 15 ). In the experiments described here, we
have inhibited ODC in the K14-MEK mice by crossing them with both K5-AZ and K6-AZ mice. K14-MEK mice on
the ICR background were crossed with K5-AZ and K6-AZ mice on both the carcinogenesis-resistant C57BL/6
background and the sensitive DBA/2 background. Combining expression of MEK and AZ results in a striking
decrease in both tumor incidence and multiplicity compared with MEK expression alone. MEK/AZ mice not only
form fewer tumors than K14-MEK mice, but tumors that form in MEK/AZ mice are also of dramatically reduced
size. Although all mice expressing AZ exhibited reduced tumorigenesis, the effect was most remarkable in the
MEK/K6-AZ mice from the ICR/D2 F1 cross, where double transgenic mice averaged less than one tumor per
mouse for more than 8 weeks, while K14-MEK mice averaged over 13 tumors per mouse at this age.
The tumor response induced by the K14-MEK transgene was much more pronounced in mice resulting from an
ICR/D2 F1 cross than from an ICR/B6 cross. Although it is difficult to draw conclusions concerning strain effect on
MEK-induced tumor development using mice on mixed backgrounds, the response is similar to the DMBA/TPA
sensitivity of the DBA/2 and C57BL/6 strains, and suggests common modulators of MEK-induced tumor
development and Ras-induced tumor development in the DMBA/TPA model ( 36 ). Multiple genetic loci are
known to affect the susceptibility of mice to skin tumor formation ( 36 , 37 ), and genes that may modify
polyamine-dependent susceptibility to skin tumorigenesis are beginning to be explored ( 38 ). The AZoverexpressing mice may therefore be useful in future experiments designed to answer this question.
AZ expression does not completely prevent tumorigenesis in K14-MEK mice, and tumors do develop over time in
MEK/AZ mice, although far fewer and much smaller tumors were observed. ODC activity is 50–60% lower in
double transgenic tumors, suggesting that the rate of tumor growth can be correlated with the level of ODC. It
has been shown very recently using Odc+/− mice that a modest reduction in ODC activity can lead to a marked
resistance to tumor development ( 39 ). Most of the reduction in ODC activity in MEK/K6-AZ tumors can be
accounted for by AZ expression in the suprabasal cell layer. Putrescine is decreased in MEK/K6-AZ tumors,
reflecting the higher AZ expression in the MEK/K6-AZ tumors. This result suggests that the primary role played
by AZ in this system is to inhibit putrescine accumulation by either inhibiting ODC activity or stimulating ODC
protein degradation. The correlation between putrescine content and tumor growth or inhibition is consistent
with several other skin tumor models, including Ptch1 +/− /AZ mice ( 20 ), our results in K14-MEK mice using
DFMO ( 15 ), and results in either K5-ODC mice ( 12 ) or ODC/Ras double transgenic mice ( 13 ) treated with
DFMO. Conversely, large increases in putrescine were observed in tumors from mice overexpressing the
polyamine catabolic enzyme spermidine/spermine N 1 -acetyltransferase (SSAT) driven by the K6 promoter
( 40 ). Interestingly, an unusually high number of tumors rapidly progressed to carcinomas in K6-SSAT mice on
the C57BL/6 background ( 40 ).

AZ staining in the proliferating basal layer of MEK/K5-AZ tumors as seen by immunohistochemistry is of very low
intensity. However, ODC activity is reduced by about 50% in all MEK/K5-AZ tumors, suggesting enough AZ is
present in these tumors to inhibit ODC. Although induction of K6-AZ expression caused by hyperproliferation of
the tumor cells in MEK/K6-AZ tumors is sufficient to reduce overall putrescine levels, the more localized
expression of the K5-AZ transgene in tumors results in an absence of measurable changes in putrescine in
MEK/K5-AZ whole tumor extracts.
In spite of the obvious difference in tumor size between MEK and MEK/AZ mice, nuclear PCNA expression results
suggest similar growth in all tumors at the time of sacrifice. Quantitation of tumor BrdU staining of cells in Sphase revealed a 15–20% difference between MEK and MEK/AZ tumors. This is accompanied by a 40% decrease
in mitotic cells in MEK/K5-AZ tumors and more than a 60% decrease in MEK/K6-AZ tumors. These results suggest
that AZ inhibits tumor growth primarily by prolonging the transit time between G 2 and M phases of the cell
cycle. ODC activity is known to behave in a biphasic manner in the cell cycle, with one peak in late G 1 and a
second, higher peak in G 2 ( 41 – 44 ). The constitutive AZ expression in these transgenic lines would presumably
inhibit both these peaks of activity. The results presented here therefore suggest that inhibition of ODC in
G 1 has a moderate effect on the G 1 /S transition, while blocking ODC in G 2 has a greater effect on mitosis.
Recent results have implicated AZ in the proteasomal degradation of other proteins, including Smad 1 ( 45 ) and
cyclin D1 ( 46 ). While the results reported here do not rule out the possibility that the delay in cell cycle
progression seen in MEK/AZ tumors may be a combination of polyamine depletion and changes in cyclin D1
activity, we did not detect any difference in cyclin D1 expression in MEK and MEK/AZ skin or tumors in this
model (results not shown). In addition, the effect of AZ was more pronounced at G 2 /M rather than G 1 /S,
suggesting that it is not related to alterations in cyclin D1 levels or activity, which peak in G 1 ( 44 ).
In contrast to our results with DFMO-treated K14-MEK mice ( 15 ), MEK/AZ tumors did not show strong evidence
of apoptosis, suggesting that the primary effect of AZ is on cell growth in this model. The previous DFMO
experiments analyzed apoptosis in established tumors, while the current experiments measure apoptosis rates
in developing tumors. DFMO has also been reported to reduce tumor vascularization ( 13 ), which may lead to
increased rates of apoptosis due to effects that are not tumor-cell autonomous. Overexpression of AZ from the
K5 promoter was found to protect zinc-deficient mice from forestomach carcinogenesis brought about by
exposure to N-nitrosomethylbenzylamine both by inhibiting uncontrolled cell proliferation and stimulating
apoptosis ( 47 ). The distinct downstream pathways activated by chemical initiation versus expression of a
specific gene such as MEK are likely to contribute to the differing effects of AZ in these models. Tissue specific
responses to oncogenic stimuli are also likely to influence these results, and it has been suggested that the
primary protective response of keratinocytes may be a program of differentiation rather than apoptosis ( 48 ).
The tumors in K14-MEK mice appear as well-differentiated papillomas, and the necessity to sacrifice the K14MEK mice at relatively young ages due to large tumor burden leaves in question the effect of AZ expression on
progression to carcinomas. Backcrosses of K14-MEK mice onto the FVB strain, which are more susceptible to the
development of carcinomas ( 38 ), will perhaps provide insight into whether AZ can act to inhibit carcinoma
formation in a manner similar to that already seen for DFMO ( 13 , 49 , 50 ). This will also facilitate additional
genetic studies of the pathways that influence MEK-induced carcinogenesis through the combination of the K14MEK transgene with other transgenic and knockout models.
In summary, the results obtained from these experiments suggest strongly that skin tumorigenesis in response
to Ras activation requires an increase in polyamine metabolism, and AZ can act as a tumor suppressor in this
model. The results suggest that AZ expression inhibits tumor growth by reducing ODC activity and tumor
putrescine accumulation. The inhibition of tumor proliferation appears to be mediated by a mechanism
involving a moderate increase in G 1 and a greater increase in G 2 transit times, without inducing apoptosis.

These double transgenic MEK/AZ mice thus provide an excellent model in which to identify growth-related
genes and proteins downstream of Ras that are altered in the presence of AZ.
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K14-MEK mice used in these experiments were supplied by Bristol-Myers Squibb. This work was supported by
grant CA-82768 from the NCI (L.M.S.).
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